Arcus Biosciences Inc RCUS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RCUS is a good fit for your portfolio.
News
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
Trading Information
- Previous Close Price
- $14.59
- Day Range
- $14.51–15.19
- 52-Week Range
- $12.95–25.47
- Bid/Ask
- $14.65 / $14.81
- Market Cap
- $1.33 Bil
- Volume/Avg
- 450,974 / 813,546
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 577
- Website
- https://www.arcusbio.com
Comparables
Valuation
|
Metric
|
RCUS
|
CLDX
|
TYRA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.43 | 5.02 | 3.15 |
Price/Sales | 9.39 | 271.21 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
RCUS
CLDX
TYRA
Financial Strength
|
Metric
|
RCUS
|
CLDX
|
TYRA
|
|---|---|---|---|
Quick Ratio | 4.35 | 13.69 | 13.27 |
Current Ratio | 4.52 | 13.87 | 13.80 |
Interest Coverage | −170.00 | — | — |
Quick Ratio
RCUS
CLDX
TYRA
Profitability
|
Metric
|
RCUS
|
CLDX
|
TYRA
|
|---|---|---|---|
Return on Assets (Normalized) | −20.42% | −30.49% | −22.50% |
Return on Equity (Normalized) | −44.44% | −33.19% | −23.73% |
Return on Invested Capital (Normalized) | −49.53% | −32.85% | −27.79% |
Return on Assets
RCUS
CLDX
TYRA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lfqlhvpqd | Hbb | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lfvrkpw | Dgwfvp | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jjflmlqz | Hxhwf | $98.8 Bil | |
MRNA
| Moderna Inc | Sxrccxp | Lxbbv | $38.8 Bil | |
ARGX
| argenx SE ADR | Kstfwvnh | Fmn | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Tmgvpww | Fvjb | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vpztbkgls | Vhshtr | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pyvddss | Tndgblj | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mkcbbvxj | Yvlzr | $12.4 Bil | |
INCY
| Incyte Corp | Lglykbj | Hdjcg | $11.9 Bil |